Hot Stock List : Broadcom Corp. (NASDAQ:BRCM), Canadian Solar (NASDAQ:CSIQ), Genworth Financial (NYSE:GNW), Rosetta Genomics (NASDAQ:ROSG), Haemonetics Corporation (NYSE:HAE)

Broadcom Corporation (NASDAQ: BRCM), a global innovation leader in semiconductor solutions for wired and wireless communications, today announced Telefonica, one of the top global telecommunications providers with operations in Europe, Asia, North America and South America, has chosen Broadcom’s HEVC-enabled system-on-chip (SoC) technology to deliver Ultra High Definition (Ultra HD) IPTV broadcasts. Broadcom Corp. (NASDAQ:BRCM) belongs to Technology sector. Its net profit margin is 7.90% and weekly performance is -2.17%. On last trading day company shares ended up $37.05. Broadcom Corp. (NASDAQ:BRCM) distance from 50-day simple moving average (SMA50) is -0.61%.

Canadian Solar Inc. (NASDAQ:CSIQ) has said that it has powered 4 MW Spanish Estate Solar Project based in St. Croix. It has supplied 4 MW of Canadian Solar PV modules. The Spanish Town Estate Solar Project was acquired by NRG Energy Inc (NYSE:NRG). The project utilizes almost 14,400 high efficiency solar PV modules. Canadian Solar Inc. (NASDAQ:CSIQ) shares increased 1.95% in last trading session and ended the day at $25.65. CSIQ Gross Margin is 17.20% and its return on assets is 1.60%. Canadian Solar Inc. (NASDAQ:CSIQ) quarterly performance is -5.87%.

Genworth Financial, Inc. (NYSE:GNW) had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $16.00 price target on the stock, down previously from $19.00. They wrote, “We have been Underweight on Genworth reflecting our concerns over the impact of the FHFA capital eligibility rules, long?term care exposures, and weak sales prospects, which we see limiting ROE improvement. On 06 August, Genworth Financial, Inc. (NYSE:GNW) shares increased 0.15% and was closed at $13.00. GNW EPS growth in last 5 year was 22.50%. Genworth Financial, Inc. (NYSE:GNW) year to date (YTD) performance is -16.29%.

Rosetta Genomics, Ltd. (NASDAQ:ROSG) on July 31 announces that it has signed an agreement with a global pharmaceutical company (GPC) in the area of Alzheimer’s disease (AD) diagnostics. Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD. Rosetta will leverage the GPC’s expertise in AD as it is considered a pioneer in the development and commercialization of therapeutics for AD. Rosetta Genomics, Ltd. (NASDAQ:ROSG) ended the last trading day at $3.82. Company weekly volatility is calculated as 5.96%and price to cash ratio as 1.63. Rosetta Genomics, Ltd. (NASDAQ:ROSG) showed a weekly performance of -3.54%.

Haemonetics Corporation (NYSE:HAE) CEO Brian Concannon unloaded 4,380 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $35.27, for a total transaction of $154,482.60. Following the completion of the sale, the chief executive officer now directly owns 130,307 shares of the company’s stock, valued at approximately $4,595,928. Haemonetics Corporation (NYSE:HAE) shares moved down -0.61% in last trading session and ended the day on $36.01. HAE Gross Margin is 49.90% and its return on assets is 2.40%. Haemonetics Corporation (NYSE:HAE) quarterly performance is 12.67%.